^
4ms
New P1 trial • Combination therapy • Tumor mutational burden • Metastases
|
TMB (Tumor Mutational Burden)
|
paclitaxel • Tyvyt (sintilimab) • IBI110
10ms
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=6, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=40 --> 6 | Trial completion date: Apr 2023 --> Dec 2023 | Recruiting --> Terminated; Development strategy adjustment
Enrollment change • Trial completion date • Trial termination • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
Tyvyt (sintilimab) • IBI110
1year
New P2 trial • Metastases
|
Tyvyt (sintilimab) • IBI110
over1year
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=60, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
Trial completion • Trial completion date • Trial primary completion date • Combination therapy
|
cisplatin • carboplatin • Tyvyt (sintilimab) • etoposide IV • IBI110
over1year
Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study. (ASCO 2023)
IBI110 in combination with sintilimab and XELOX demonstrated manageable safety and encouraging efficacy results in patients with first-line gastric adenocarcinoma. This is the first positive trial to show clinical benefits of a LAG3 plus PD-1 inhibitor combined with chemotherapy for this population. Clinical trial information: NCT04085185.
Clinical • P1 data • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • LAG3 (Lymphocyte Activating 3)
|
HER-2 negative
|
Tyvyt (sintilimab) • capecitabine • oxaliplatin • IBI110
2years
Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
Tyvyt (sintilimab) • IBI110
over2years
Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study. (ASCO 2022)
Background: Sintilimab plus XELOX has been proven to be efficacious in the first line treatment of gastric cancer. In this phase Ib study, IBI110 in combination with sintilimab and chemotherapy was well tolerated in the first line treatment of G/GEJ AC and the clinical benefit need more follow up time to be elucidated.
Clinical • P1 data • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Tyvyt (sintilimab) • capecitabine • oxaliplatin • IBI110
almost3years
Clinical • Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
Tyvyt (sintilimab) • IBI110
3years
Clinical • New P1 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement
|
Tyvyt (sintilimab) • IBI110